For most of my career the word vaccine meant prevention. Flu shots, shingles shots, childhood schedules. This month a different kind of vaccine made headlines. A personalized mRNA cancer vaccine built from each patient's own tumor helped keep melanoma from coming back in a large late stage trial. Patients are already asking about it, and many of us are trying to sort the real progress from the hype.
Here is what the results show, what they do not show yet, and how to talk about them in the exam room.
The vaccine is called intismeran autogene, developed by Moderna and Merck. The trial enrolled more than 1,100 people with high risk melanoma that had already been surgically removed. Every patient received pembrolizumab, the current standard follow up treatment. Half were also randomly assigned to the custom vaccine and the rest to a placebo.
At two years the vaccine group had about a 42 percent lower risk of the melanoma returning. Put more simply, roughly 82 percent of patients on the combination were still free of recurrence compared with about 70 percent on pembrolizumab alone. The detailed data were presented this month at the ESMO meeting in Madrid and confirmed that the trial met its key goals.
Side effects looked familiar. Mostly a sore arm, fatigue and the kind of short lived reactions many people remember from COVID vaccines.
Every tumor carries mutations that make its cells look slightly different from normal tissue. Some of those mutations produce new protein fragments called neoantigens. The immune system can learn to recognize them, but tumors are good at staying hidden.
A personalized cancer vaccine tries to fix that. The tumor is sequenced, its unique neoantigens are identified, and an mRNA sequence is written that teaches the body to make those targets. The immune system then gets a clear picture of what to hunt. Pembrolizumab works on the other side of the problem by releasing the brakes that tumors put on T cells. One drug points the immune system at the right target. The other lets it act.
This is the same mRNA platform that made the COVID vaccines possible, now aimed at a single patient's cancer instead of a virus.
Checkpoint inhibitors changed melanoma care over the past decade. Still, a meaningful share of patients relapse even after surgery and adjuvant therapy. Those are the conversations we dread. Lowering the risk of melanoma recurrence after surgery has been a goal for years, and every incremental gain has been hard won. An mRNA cancer vaccine that adds benefit on top of pembrolizumab, without heavy new toxicity, is a meaningful step.
What makes this result notable is not only the size of the benefit. It is the proof that an individualized mRNA cancer vaccine can be manufactured for hundreds of patients and add real value on top of strong standard care. That opens the door for cancer immunotherapy to become more personal, built around the specific biology of one tumor rather than a population average.
Similar vaccines are already being tested in lung, kidney and pancreatic cancer. Melanoma has many mutations, which makes it a good first target. Whether the approach works as well in tumors with fewer mutations is the open question oncologists are now debating.
Picture a patient two years out from a stage III melanoma resection. She saw the news on her phone and arrives at a routine visit asking whether she should get the new vaccine.
The honest answer is warm but clear. It is not approved yet. It was studied in patients starting treatment right after surgery, so it may not apply to someone further along. The companies are talking with regulators, and the trial is still following patients to see how long the benefit lasts and whether it improves survival.
A few points help keep these conversations grounded:
The vaccine is not available outside clinical trials right now.
It was given together with immunotherapy, not instead of it.
The results are for melanoma only so far.
Clinical trials for other cancers may be worth asking an oncologist about.
Most patients do not need every detail. They need to know we are watching the science closely and that their current plan is still sound.
Even with approval, getting this into routine care will take work. Each vaccine is made for one person. The tumor has to be sequenced and the vaccine produced and shipped, a process that currently takes about six weeks or longer. That means coordination between surgeons, pathologists and oncologists so tissue is handled correctly from the start.
Cost is another unknown. Pricing has not been announced, and a therapy made for a single patient will not be cheap. Payers will want to see durable benefit before covering it widely. Access could also become uneven, with large cancer centers moving first and community practices waiting.
Think of a community oncologist who sees a newly resected melanoma patient a year from now. If the vaccine is approved, the first question will be whether the surgical specimen was preserved in a way that allows sequencing. Small steps like that will decide who actually benefits.
Over the next year or two we should learn more about long term outcomes, including overall survival. Regulators will weigh the data. Trials in other cancers will start to report. Each of those milestones will tell us whether this is a melanoma story or the start of something much broader for the mRNA cancer vaccine field.
For now, a measured kind of excitement seems right. The science is real. The benefit in this trial is meaningful. And the questions about access, cost and durability are the right ones to keep asking.
It is not often that a single study reshapes how we talk about cancer recurrence with our patients. This one might. Many of us will field questions about personalized vaccines long before they reach our formularies, and we will do it better if we learn from each other.
Have patients started asking you about the melanoma vaccine? Are you referring to cancer vaccine trials or seeing them in your practice? Share your experience and questions with colleagues in the MedSocially community. Your perspective can help other physicians give patients clear and honest answers.
Physicians are tired. But exhaustion alone does not explain what many of us feel at the end of a clinic day. There is a particular kind of distress that comes from knowing exact...
Most of us know a colleague who keeps a chatbot open in a second browser tab. Maybe that colleague is you. Shadow AI in healthcare is the quiet use of AI tools that your hospita...
The patient is explaining her symptoms. The physician is listening, making eye contact and asking follow up questions. There is no constant typing and no computer screen competi...
High cholesterol is one of those health problems that can quietly develop without causing any noticeable symptoms. You may feel perfectly healthy, go about your daily routine, a...
